Geode Capital Management LLC Has $749,000 Holdings in Genelux Co. (NASDAQ:GNLX)

Geode Capital Management LLC grew its holdings in shares of Genelux Co. (NASDAQ:GNLX) by 39.7% in the 3rd quarter, Holdings Channel reports. The fund owned 316,160 shares of the company’s stock after buying an additional 89,854 shares during the period. Geode Capital Management LLC’s holdings in Genelux were worth $749,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently made changes to their positions in the stock. Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of Genelux during the 2nd quarter valued at approximately $39,000. Brown Brothers Harriman & Co. boosted its position in Genelux by 76.2% in the third quarter. Brown Brothers Harriman & Co. now owns 21,075 shares of the company’s stock valued at $50,000 after buying an additional 9,114 shares in the last quarter. Cubist Systematic Strategies LLC bought a new stake in shares of Genelux during the second quarter worth $56,000. XTX Topco Ltd acquired a new position in shares of Genelux during the third quarter worth $59,000. Finally, Miracle Mile Advisors LLC lifted its stake in shares of Genelux by 33.3% in the 3rd quarter. Miracle Mile Advisors LLC now owns 40,000 shares of the company’s stock valued at $95,000 after acquiring an additional 10,000 shares during the last quarter. Institutional investors own 37.33% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on GNLX shares. Guggenheim assumed coverage on Genelux in a research report on Tuesday, October 29th. They set a “buy” rating and a $8.00 price objective on the stock. HC Wainwright reduced their price target on Genelux from $32.00 to $30.00 and set a “buy” rating on the stock in a report on Friday, November 15th. Four analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Buy” and a consensus target price of $18.25.

Genelux Stock Up 1.2 %

Shares of Genelux stock opened at $2.58 on Friday. The stock has a market cap of $89.11 million, a price-to-earnings ratio of -2.72 and a beta of -1.68. Genelux Co. has a twelve month low of $1.60 and a twelve month high of $13.97. The company’s fifty day moving average is $2.60 and its 200 day moving average is $2.43.

Genelux Profile

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer.